Aller au contenu principal
xMedica

NCT07624305ClinicalTrials.gov

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

A Phase III, Randomised, Double-blind, Study to Evaluate the Effect of Balcinrenone/Dapagliflozin Compared With Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Chronic Kidney Disease (Stage 3b and 4)

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered…

Phase 32 800 participants recherchés478 sites27 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-06-03; recorded start 2026-09-01
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,800 participants (target), run at 478 sites, across 27 countries.

How this score is built
  • Enrolment34/40

    2,800 participants (target)

  • Site count19/25

    45 sites

  • Country count12/15

    8 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale10/10

    AstraZeneca has led 999 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.

This is a Phase III, multicentre, randomised, double-blind, double-dummy, parallel-group, active-controlled, event-driven study in participants with CKD Stage 3b and 4. The purpose of this study is to determine if balcinrenone/dapagliflozin, compared with dapagliflozin, administered as a capsule once daily on a background of standard of care (SoC) therapy, reduces the risk of CV death, death from kidney failure, kidney failure, sustained ≥ 50% decline from baseline in eGFR, and HF events in adults with CKD Stage 3b and 4. The study will also assess safety and tolerability of balcinrenone/dapagliflozin. Eligible patients will randomly be assigned with a 1:1 ratio to receive once daily administration of one capsule and one tablet of one of the following treatments: 1. Balcinrenone/dapagliflozin 15 mg/10 mg capsule and matching placebo for dapagliflozin 10 mg tablet 2. Dapagliflozin 10 mg tablet and matching placebo for balcinrenone/dapagliflozin capsule The study will be conducted at approximately 550 sites in approximately 30 countries, globally.

Affections

  • Renal Insufficiency, Chronic

Éligibilité

Éligibilité
SexeTous
Âges18 Years – 99 Years
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria: * Age ≥ 18 years * Diagnosis of CKD and at least one of the following: 1. eGFR ≥ 15 to \< 45 mL/min/1.73 m2 AND: UACR ≥ 30 mg/g (central laboratory) or UACR ≥ 100 mg/g (local laboratory ) or UPCR ≥ 200 mg/g (local laboratory). 2. eGFR ≥ 15 to \< 30 mL/min/1.73 m2 and UACR \< 30 mg/g (local or central laboratory UACR value). * Serum/plasma K+ ≤ 5.0 mmol/L * Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening. Exclusion Criteria: * Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation * UACR ≥ 5000 mg/g or UPCR ≥ 7000 mg/g at screening. * SBP \> 180 mmHg or DBP \> 110 mmHg at screening. * SBP \< 90 mmHg at screening. * HbA1c \> 9% at screening * T1DM, except: 1. For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible. 2. For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion. * Autosomal dominant polycystic kidney disease. * Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening. * Severe hepatic impairment (Child-Pugh Class C). * Adrenal insufficiency. * Clinically significant acute kidney injury within 12 weeks prior to the screening. * New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening. * Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening. * Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation. * Any use of the following medications and supplements: 1. MRAs 2. Aldosterone analogues 3. Aldosterone synthase inhibitors 4. Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation. 5. Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one week prior to randomisation

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement2 800 participants recherchés

Promoteur et collaborateurs

  • AstraZeneca Promoteur

Groupes et interventions

  • Balcinrenone/dapagliflozinEXPERIMENTAL

    Patient receives once daily 1 capsule balcinrenone 15 mg and dapagliflozin 10 mg and 1 placebo tablet matching dapagliflozin.

  • DapagliflozinACTIVE_COMPARATOR

    Patient receives once daily 1 placebo capsule matching balcinrenone and dapagliflozin and 1 tablet dapagliflozin 10 mg.

Interventions

  • Médicament Balcinrenone/dapagliflozin

    balcinrenone/dapagliflozin 15 mg/10 mg

  • Médicament Dapagliflozin

    dapagliflozin 10 mg

  • Médicament Placebo matching Dapagliflozin

    matching placebo for dapagliflozin 10 mg

  • Médicament Placebo matching balcinrenone/dapagliflozin

    matching placebo for balcinrenone/dapagliflozin

Critères de jugement

  1. Critère de jugement principal

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure, sustained 50% or greater decline in eGFR, and heart failure event

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure * Initiation of maintenance dialysis or * Kidney transplantation * Sustained ≥ 50% decline from baseline in eGFR * HF with or without hospitalisation

    Délai Up to 46 months.

  2. Critère de jugement secondaire

    Time to first occurrence of cardiovascular death, death from kidney failure, kidney failure and sustained 50% or greater decline in eGFR.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * Death from kidney failure * Onset of kidney failure: * Initiation of maintenance dialysis or * Kidney transplantation Sustained ≥ 50% decline from baseline in eGFR

    Délai Up to 46 months.

  3. Critère de jugement secondaire

    Change in urinary albumin to creatinine ratio to Week 24

    Change from baseline to Week 24 in urinary albumin to creatinine ratio

    Délai Baseline to Week 24

  4. Critère de jugement secondaire

    Time to first occurrence of cardiovascular death or heart failure event.

    Time from randomization to first occurrence of any of the components of the composite: * CV death * HF with or without hospitalisation

    Délai Up to 46 months.

  5. Critère de jugement secondaire

    Time to cardiovascular death

    Time from randomization to cardiovascular death.

    Délai Up to 46 months.

  6. Critère de jugement secondaire

    Time to death from any cause

    Time from randomization to death from any cause.

    Délai Up to 46 months.

Dates

Dates
Date de début1 septembre 2026 (réelle)
Achèvement principal1 juillet 2030 (estimée)
Achèvement1 juillet 2030 (estimée)
Première publication3 juin 2026 (réelle)
Dernière mise à jour24 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

33 sites sont en recrutement

Argentina

Argentina
ÉtablissementVilleÉtat ou régionStatut
Research SiteCABAPas encore en recrutement
Research SiteCapital FederalPas encore en recrutement
Research SiteCiudad de Buenos AiresPas encore en recrutement
Research SiteLa PlataPas encore en recrutement
Research SiteLanús EstePas encore en recrutement
Research SiteMar del PlataPas encore en recrutement
Research SiteRosarioPas encore en recrutement
Research SiteRosarioPas encore en recrutement
Research SiteRosarioPas encore en recrutement
Research SiteSan NicolásPas encore en recrutement
Research SiteSanta FePas encore en recrutement
Research SiteSanta FePas encore en recrutement

Austria

Austria
ÉtablissementVilleÉtat ou régionStatut
Research SiteFeldkirchPas encore en recrutement
Research SiteInnsbruckPas encore en recrutement
Research SiteLinzPas encore en recrutement
Research SiteSankt PöltenPas encore en recrutement
Research SiteViennaPas encore en recrutement
Research SiteViennaPas encore en recrutement
Research SiteViennaPas encore en recrutement
Research SiteViennaPas encore en recrutement
Research SiteWelsPas encore en recrutement
Research SiteWiener NeustadtPas encore en recrutement

Brazil

Brazil
ÉtablissementVilleÉtat ou régionStatut
Research SiteBarretosPas encore en recrutement
Research SiteBelo HorizontePas encore en recrutement
Research SiteBelo HorizontePas encore en recrutement
Research SiteBelémPas encore en recrutement
Research SiteCampinasPas encore en recrutement
Research SiteGoiâniaPas encore en recrutement
Research SiteNatalPas encore en recrutement
Research SiteRecifePas encore en recrutement
Research SiteSão Caetano do SulPas encore en recrutement
Research SiteSão José do Rio PretoPas encore en recrutement
Research SiteSão José dos CamposPas encore en recrutement
Research SiteSão PauloPas encore en recrutement
Research SiteSão PauloPas encore en recrutement
Research SiteSão PauloPas encore en recrutement
Research SiteSão PauloPas encore en recrutement

Bulgaria

Bulgaria
ÉtablissementVilleÉtat ou régionStatut
Research SiteBlagoevgradPas encore en recrutement
Research SiteNova ZagoraPas encore en recrutement
Research SitePlevenPas encore en recrutement
Research SitePlovdivPas encore en recrutement
Research SiteSandanskiPas encore en recrutement
Research SiteSevlievoPas encore en recrutement
Research SiteSofiaPas encore en recrutement
Research SiteSofiaPas encore en recrutement
Research SiteSofiaPas encore en recrutement
Research SiteStara ZagoraPas encore en recrutement
Research SiteVarnaPas encore en recrutement

Canada

Canada
ÉtablissementVilleÉtat ou régionStatut
Research SiteBramptonOntarioPas encore en recrutement
Research SiteCalgaryAlbertaRetiré

428 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 24 septembre 2026

    Statut modifié

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. 24 septembre 2026

    Recrutement ouvert

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING

  3. 24 septembre 2026

    Site ajouté

    433 sites added (478 total)

    45478